Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary therapy for multiple sclerosis (MS) after completing Phase 1 clinical studies that demonstrated a favorable safety profile and tolerability in healthy volunteers. The company’s LUCID-MS program focuses on an unmet need for treatments that can directly protect or restore myelin integrity, which is critical for preserving mobility and bodily control in MS patients.
Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers. As myelin deteriorates, nerve communication is disrupted, leading to symptoms that can include loss of mobility. The disease affects more than 2.8 million people worldwide and approximately 1 million in the United States. Many patients continue to experience worsening disability despite available immune-modulating therapies, which often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression.
Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS. The therapy is designed to target demyelination and provide neuroprotection, potentially addressing the loss of mobility and function that MS patients face. Current treatments often fall short in halting disease progression, highlighting the importance of novel approaches like LUCID-MS.
For more information on Quantum BioPharma and its developments, visit the company’s newsroom at https://ibn.fm/QNTM.
This announcement comes as the biotech sector continues to seek effective therapies for neurodegenerative conditions. The favorable Phase 1 results and IND submission represent crucial steps toward potentially offering MS patients a treatment that directly targets the root cause of disability. While further studies are needed, the progress of LUCID-MS underscores the ongoing efforts to fill the therapeutic gap in MS care.
